The use of hair as a long‐term indicator of low‐dose β2 agonist treatments in cattle: Implications for growth‐promoting purposes monitoring. Issue 6 (6th January 2019)
- Record Type:
- Journal Article
- Title:
- The use of hair as a long‐term indicator of low‐dose β2 agonist treatments in cattle: Implications for growth‐promoting purposes monitoring. Issue 6 (6th January 2019)
- Main Title:
- The use of hair as a long‐term indicator of low‐dose β2 agonist treatments in cattle: Implications for growth‐promoting purposes monitoring
- Authors:
- Liu, Jia
Tang, Chaohua
Long, Ruijun
Zhang, Kai
Han, Yunsheng
Zhao, Qingyu
Wang, Hongliang
Zhao, Fuzhong
Meng, Qingshi
Zhang, Junmin - Abstract:
- Abstract: The objective of this study was to assess the feasibility of using hair as a long‐term indicator of cocktail (low‐dose β2 agonists) treatments in cattle. Six male Simmental cattle were treated with a mixture of low‐dose clenbuterol, ractopamine, and salbutamol at dosages of 5.3, 223.3, and 50.0 μg/kg, respectively. The trial lasted for 112 days and included 28 days of treatment and 84 days of withdrawal. Plasma and urine samples taken during the treatment period contained the highest residues, with maximum concentrations of clenbuterol, ractopamine, and salbutamol in plasma of 1.49 ng/mL (Day 21), 43.78 (Day 14) ng/mL, and 8.07 ng/mL (Day 7), respectively, and in urine of 62.40 ng/mL (Day 28), 3995.77 ng/mL (Day 28), and 503.72 ng/mL (Day 1), respectively. On day 42 of withdrawal, the residues of all three β2 agonists in plasma were below the limit of quantification (LOQ; 0.3 ng/mL for clenbuterol, and 0.5 ng/mL for ractopamine and salbutamol), and in urine samples were below or near the LOQ (the highest being ractopamine at 1.10 ng/mL). The highest concentrations of clenbuterol, ractopamine, and salbutamol in hair were 88.36, 1351.92, and 100.58 ng/g, respectively, on day 14 of withdrawal; and the residues were long‐lasting, with 7.64, 28.55, and 8.77 ng/g, respectively, on day 84 of withdrawal. The results of this study demonstrate that hair could be utilized as a long‐term indicator of the use of a combination of low‐dose β2 agonists in cattle, which could haveAbstract: The objective of this study was to assess the feasibility of using hair as a long‐term indicator of cocktail (low‐dose β2 agonists) treatments in cattle. Six male Simmental cattle were treated with a mixture of low‐dose clenbuterol, ractopamine, and salbutamol at dosages of 5.3, 223.3, and 50.0 μg/kg, respectively. The trial lasted for 112 days and included 28 days of treatment and 84 days of withdrawal. Plasma and urine samples taken during the treatment period contained the highest residues, with maximum concentrations of clenbuterol, ractopamine, and salbutamol in plasma of 1.49 ng/mL (Day 21), 43.78 (Day 14) ng/mL, and 8.07 ng/mL (Day 7), respectively, and in urine of 62.40 ng/mL (Day 28), 3995.77 ng/mL (Day 28), and 503.72 ng/mL (Day 1), respectively. On day 42 of withdrawal, the residues of all three β2 agonists in plasma were below the limit of quantification (LOQ; 0.3 ng/mL for clenbuterol, and 0.5 ng/mL for ractopamine and salbutamol), and in urine samples were below or near the LOQ (the highest being ractopamine at 1.10 ng/mL). The highest concentrations of clenbuterol, ractopamine, and salbutamol in hair were 88.36, 1351.92, and 100.58 ng/g, respectively, on day 14 of withdrawal; and the residues were long‐lasting, with 7.64, 28.55, and 8.77 ng/g, respectively, on day 84 of withdrawal. The results of this study demonstrate that hair could be utilized as a long‐term indicator of the use of a combination of low‐dose β2 agonists in cattle, which could have implications for growth‐promoting purposes monitoring. Abstract : This study assessed the feasibility of using hair as a long‐term indicator of low‐dose β2 agonist treatments in cattle. On day 42 of withdrawal, the residues of the β2 agonists in plasma and urine were below or near the LOQ, while which in hair were more than 7.64 ng/g on day 84 of withdrawal. Hair could be utilized as a long‐term indicator of the use of a combination of low‐dose β2 agonists. … (more)
- Is Part Of:
- Drug testing and analysis. Volume 11:Issue 6(2019)
- Journal:
- Drug testing and analysis
- Issue:
- Volume 11:Issue 6(2019)
- Issue Display:
- Volume 11, Issue 6 (2019)
- Year:
- 2019
- Volume:
- 11
- Issue:
- 6
- Issue Sort Value:
- 2019-0011-0006-0000
- Page Start:
- 745
- Page End:
- 751
- Publication Date:
- 2019-01-06
- Subjects:
- growth‐promoting purposes -- hair -- monitoring -- residues -- β2 agonists
Drugs -- Analysis -- Periodicals
Drug testing -- Periodicals
Chemistry, Forensic -- Periodicals
615.1901 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1942-7611 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=110501 ↗
http://www3.interscience.wiley.com/journal/121408477/home ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/dta.2551 ↗
- Languages:
- English
- ISSNs:
- 1942-7603
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3629.424000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 10861.xml